Lifecore Biomedical Inc
NASDAQ:LFCR
Lifecore Biomedical Inc
Additional Paid In Capital
Lifecore Biomedical Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lifecore Biomedical Inc
NASDAQ:LFCR
|
Additional Paid In Capital
$206.9m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Hershey Co
NYSE:HSY
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
General Mills Inc
NYSE:GIS
|
Additional Paid In Capital
$1.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-1%
|
|
|
Kellogg Co
NYSE:K
|
Additional Paid In Capital
$1.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Kraft Heinz Co
NASDAQ:KHC
|
Additional Paid In Capital
$52.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Mondelez International Inc
NASDAQ:MDLZ
|
Additional Paid In Capital
$32.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
Lifecore Biomedical Inc
Glance View
Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. The company is headquartered in Chaska, Minnesota and currently employs 689 full-time employees. The firm offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials, as well as the manufacture of pharmaceutical-grade Hyaluronic Acid. The company provides complete CDMO services for injectable pharmaceuticals and medical devices. The Company’s services include sodium hyaluronate, development, manufacturing, and analytical services. The company offers a range of average molecular weights and custom modifications for research and development (R&D), clinical, and commercial applications. The Company’s therapeutic applications include drug delivery, biomaterials, ophthalmology, orthopedics, aesthetics, oncology, and pain management. Its development capabilities include formulation, sterile filtration, filling, packaging, testing, and secondary sterilization.
See Also
What is Lifecore Biomedical Inc's Additional Paid In Capital?
Additional Paid In Capital
206.9m
USD
Based on the financial report for Nov 24, 2024, Lifecore Biomedical Inc's Additional Paid In Capital amounts to 206.9m USD.
What is Lifecore Biomedical Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
5%
Over the last year, the Additional Paid In Capital growth was 17%. The average annual Additional Paid In Capital growth rates for Lifecore Biomedical Inc have been 8% over the past three years , 5% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet